Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis

Journal of the American Academy of Dermatology

Volumn 44, Issue 3, 2001, Pages 485-491

  Gupta, Aditya K ^a   Lynde, Charles W ^b   Konnikov, Nellie ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; TERBINAFINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONYCHOMYCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; SINGLE BLIND PROCEDURE; TASTE DISORDER; TOE;

EID: 0035098972     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.110644     Document Type: Article

References (27)

1. Antifungal agents: An overview, part II
2. The new oral antifungal agents for onychomycosis of the toenails: A review
3. Treatment of dermatophyte nail infections: An open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy
4. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: A new approach
5. Terbinafine - An update
6. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition
7. Itraconazole intermittent pulse therapy is effective and safe in the treatment of onychomycosis and dermatomycoses: An overview
8. Current management of onychomycosis: An overview
9. Pharmacokinetic profile of orally administered itraconazole in human skin
10. Multidrug therapy
11. Is there a microbiological rationale for single-dose treatment of leprosy?
12. Tuberculosis treatment for the beginning of the next century
13. Trimethoprim-sulfamethoxazole in the United States
14. Successful therapy of Candida albicans arthritis with a sequential intravenous amphotericin B and oral fluconazole regimen
15. Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism
16. Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus
17. Therapeutic approach of recalcitrant toenail onychomycosis
18. New findings on the in vitro activity of antifungal agents
19. A risk-benefit assessment of the newer oral antifungal agents to treat onychomycosis
20. Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis
21. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: A double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day
22. Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis
23. Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: A multicenter trial
24. Elimination kinetics of terbinafine from human plasma and tissues following multiple-dose administration, and comparison with 3 main metabolites
25. A. Nail incorporation kinetics of terbinafine in onychomycosis patients